(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Really focusing on Succulents: Tips and Procedures - 2With Obamacare premium hikes, more people opting for no coverage or cheaper plans
- 3NASA’s history-making moon mission aims to send the first woman and person of color to deep space
- 4Instructions to Discuss Successfully with Your Auto Collision Lawyer
- 5'I carried my wife's body for an hour and a half' - BBC hears stories of protesters killed in Iran
- From Fledgling to Master: Self-awareness in a Side interest
- How Google, Microsoft, Walmart, and other corporate giants are preparing for an aging workforce
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- Los Angeles County sees significant uptick in norovirus cases, officials say
- Netanyahu expects Iran's leadership to fall
- Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- Scientists Just Discovered Japan’s First New Bird Species in Over 40 Years
- Manual for Notorious Fragrances: Immortal Aromas
- UK consumer confidence plunges amid escalating Iran conflict
